Therapeutic Effects of Matricaria chamomilla Extract in an Immunosuppressed Mouse Model of Cryptosporidiosis Authors: Kousha Kiani, Mohammad Hashemnia, Farid Rezaei, Hadi Cheraghi Published: 2026 ABSTRACT ABSTRACTBackgroundCryptosporidiosis, caused by Cryptosporidium parvum, is an opportunistic protozoan infection that can lead to severe intestinal pathology in immunocompromised hosts. Despite extensive research, current chemotherapeutic options, such as nitazoxanide and paromomycin, remain suboptimal, underscoring the need for safe and effective alternatives. Chamomile (Matricaria chamomilla L.), known for its antioxidant, anti‐inflammatory, and antiparasitic activities, has recently attracted attention as a potential phytotherapeutic agent.MethodsThis experimental study evaluated the therapeutic efficacy of a hydroalcoholic chamomile extract in immunosuppressed Swiss albino mice infected experimentally with C. parvum. Animals were divided into five groups: normal control, chamomile control, infected untreated, infected treated with paromomycin (100 mg/kg/day) and infected treated with chamomile extract (100 mg/kg/day). Oocyst shedding, intestinal histopathology and oxidative stress biomarkers were assessed at Days 0 (7 days post‐infection), and 3, 7 and 11 post‐treatment.ResultsChamomile treatment significantly reduced oocyst shedding compared with the untreated infected group (p < 0.05) and improved intestinal tissue architecture by attenuating villous atrophy, epithelial desquamation and inflammatory cell infiltration. Biochemical assays revealed that chamomile markedly increased TAC and GPx activity while reducing MDA levels. Although paromomycin showed a more rapid reduction in oocyst output, chamomile induced a gradual but sustained improvement with pronounced antioxidant and anti‐inflammatory effects.ConclusionHydroalcoholic extract of M. chamomilla was associated with reduced oocyst shedding, improved intestinal histopathology, and enhanced antioxidant status in immunosuppressed mice infected with C. parvum, supporting its potential as an adjunctive phytotherapeutic approach that warrants further mechanistic, pharmacological and long‐term investigation.Keywords: antioxidant defence, Cryptosporidium parvum, immunosuppressed mice, Matricaria chamomilla, oocyst shedding, paromomycin Introduction The genus Cryptosporidium comprises obligate intracellular protozoan parasites in the phylum Apicomplexa that infect a broad range of vertebrate hosts, including humans and livestock (Ghazy et al. 2015). Since the identification of C. muris in laboratory mice by Tyzzer in 1907, numerous studies have described the biology, epidemiology and pathogenicity of different Cryptosporidium species (Bouzid et al. 2018; Dong et al. 2020; Ryan et al. 2016). Among the known species, C. parvum is one of the most important zoonotic agents responsible for cryptosporidiosis in both humans and animals (Ryan and Hijjawi 2015; Ryan et al. 2014; Thompson and Ash 2016). The parasite colonizes the epithelial cells of the gastrointestinal tract, causing acute or chronic diarrhoea, abdominal cramps, dehydration and weight loss (Asadpour et al. 2018; Ryan and Hijjawi 2015). Cryptosporidiosis has become a significant global public health problem, particularly in immunocompromised patients, such as those with acquired immunodeficiency syndrome (AIDS), organ transplant recipients or individuals undergoing immunosuppressive therapy. In these cases, the disease may progress to a life‐threatening condition characterized by severe, persistent diarrhoea and high morbidity and mortality rates (Breurec et al. 2016; Okosun et al. 2017; Zhang and Xiao 2018). In immunocompetent hosts, the infection is generally self‐limiting, but in immunodeficient individuals, autoinfection through thin‐walled oocysts perpetuates continuous cycles of parasitism within the intestinal epithelium (Ryan et al. 2016). Transmission occurs mainly through the faecal–oral route, by ingestion of contaminated water or food or direct contact with infected hosts. The environmental resistance of oocysts, coupled with their low infectious dose, has led to numerous large‐scale waterborne and foodborne outbreaks worldwide (Berahmat et al. 2017; Robertson et al. 2020). In farm animals, C. parvum infection causes neonatal diarrhoea, growth retardation and even mortality in calves, lambs and kids, resulting in substantial economic losses due to reduced productivity and treatment costs (Buchanan et al. 2025; Gong et al. 2017). Although several chemical compounds, including metronidazole, paromomycin, nitazoxanide, azithromycin, spiramycin and bovine anti‐Cryptosporidium immunoglobulin, have been tested for treatment of Cryptosporidium infection, an effective and definitive treatment remains elusive (Namazi and Razavi 2024). Nitazoxanide, the only FDA‐approved drug, exhibits partial efficacy, especially in immunocompetent hosts, but fails to eradicate the parasite in immunocompromised patients (Gong et al. 2017; Robertson et al. 2020; Ryan et al. 2016). Paromomycin, an aminoglycoside antibiotic, has demonstrated variable results in reducing oocyst shedding and clinical symptoms, with relapse frequently occurring after treatment withdrawal (Asadpour et al. 2018). Consequently, both nitazoxanide and paromomycin remain suboptimal options, and the development of new therapeutic strategies is urgently needed (Ward 2017). In recent years, medicinal plants and their bioactive constituents have received increasing attention as promising alternative or complementary therapies for protozoan infections, due to their low toxicity, accessibility and broad pharmacological properties (Ali et al. 2024; Thakur et al. 2025). Various phytochemicals, including flavonoids, terpenoids, alkaloids and phenolic acids, have demonstrated significant antiparasitic, antioxidant and immunomodulatory effects that can interfere with protozoan growth and improve host immune responses (El‐Wakil et al. 2023; Ghareeb et al. 2023). In Cryptosporidium infections, oxidative stress and inflammatory damage play key roles in intestinal pathology, villous atrophy and oocyst shedding. Thus, antioxidant‐based therapies using plant‐derived compounds have been proposed as potential supportive strategies to attenuate the disease severity and improve intestinal recovery (Ali et al. 2024; Elghonemy et al. 2025; Ghareeb et al. 2023). Chamomile (Matricaria chamomilla L.), a member of the family Asteraceae, is one of the most extensively studied medicinal plants owing to its broad pharmacological and therapeutic properties. It contains a complex array of bioactive compounds, including flavonoids (apigenin, luteolin, quercetin), terpenoids (α‐bisabolol, bisabolol oxide, chamazulene) and coumarins (umbelliferone, herniarin), which contribute synergistically to its antioxidant, anti‐inflammatory, antimicrobial and cytoprotective activities (Ostovar et al. 2025; Sánchez et al. 2022). In vitro and in vivo studies have demonstrated that chamomile extracts exhibit potent free radical scavenging capacity and can modulate oxidative stress through enhancement of total antioxidant capacity (TAC), elevation of antioxidant enzyme activities, such as superoxide dismutase and glutathione peroxidase (GPx), and reduction of malondialdehyde (MDA) levels, thereby preventing reactive oxygen species (ROS)–induced epithelial injury (Amraei et al. 2018; Soltani et al. 2018). Apigenin, one of the main flavonoids in chamomile, has demonstrated antiparasitic, anti‐inflammatory and immunomodulatory effects, primarily by inhibiting NF‐κB signalling and downregulating proinflammatory cytokines such as TNF‐α and IL‐6 (Flemming et al. 2015). Given its well‐documented pharmacological properties, favourable safety profile, and has classified as GRAS (generally recognized as safe) by the U.S. FDA, M. chamomilla has emerged as a promising phytotherapeutic candidate for the management of oxidative and inflammatory intestinal disorders. Its phenolic and flavonoid compounds may also alleviate oxidative stress and inflammation induced by C. parvum. Therefore, the present study aimed to investigate the therapeutic and protective effects of hydroalcoholic chamomile extract against experimental C. parvum infection in immunosuppressed mice, providing novel insights into the potential application of plant‐derived compounds as adjunctive interventions for cryptosporidiosis. Materials and Methods Animals and Housing Conditions A total of 110 female Swiss albino mice (3–4 weeks old, 20–25 g), free from Cryptosporidium infection, were used in this study. The animals were obtained from a certified breeding facility and housed in the Animal Research Center under controlled conditions (temperature: 22°C–24°C; relative humidity: 40%–50%; 12 h light/12 h dark cycle) according to the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals. Mice were maintained in clean polypropylene cages with free access to standard pelleted diet and water ad libitum. After 7 days to the new conditions, the remaining steps of the experiment were performed. Immunosuppression was induced by intraperitoneal administration of dexamethasone (0.8 mg/kg) every other day for a total of six injections prior to oocyst inoculation, following a previously validated experimental protocol described by Baishanbo et al. (2005) and Asadpour et al. (2018). Drugs and Extract Preparation The hydroalcoholic extract of M. chamomilla (commercially available as Matriman, Rahman Gostaran Daru Co., Tehran, Iran) was obtained in capsule form, each containing 325 mg of M. chamomilla flower powder and extract, as specified by the manufacturer. According to the manufacturer's specifications, the product contained quantified levels of major flavonoids and phenolic acids, including apigenin‐7‐O‐glucoside (0.8–1.6 mg/g), apigenin (0.1–0.4 mg/g), luteolin‐7‐O‐glucoside (0.3–0.9 mg/g), quercetin (0.05–0.2 mg/g), rutin (0.2–0.6 mg/g), herniarin (0.1–0.4 mg/g), chlorogenic acid (1.5–3.0 mg/g) and caffeic acid (0.05–0.6 mg/g), along with trace amounts of α‐bisabolol and chamazulene in the essential oil fraction. These constituents have been previously identified in hydroalcoholic extracts of M. chamomilla by phytochemical analyses reported in the literature (Hajaji et al. 2018a; Mailänder et al. 2022; Cvetanović et al. 2015; Viapiana et al. 2016). Paromomycin sulphate (250 mg capsules; Humatin, Pfizer Italia S.r.l., Italy) was employed as the reference anti‐cryptosporidial agent. The capsule powder was freshly suspended in distilled water immediately before oral administration. C. parvum Oocysts Oocysts of C. parvum were obtained from the Parasitology Department, Faculty of Veterinary Medicine, Kermanshah University, where standard parasitological techniques had previously confirmed the isolate. Purified oocysts were suspended in 2.5% potassium dichromate solution and stored at 4°C until use. Before inoculation, the oocysts were washed three times with phosphate‐buffered saline (PBS) to remove the preservative and counted using a haemocytometer. Experimental Infection Following immunosuppression, infection was induced in designated groups by oral inoculation (gavage) of C. parvum oocysts at a dose of 1 × 105 per mouse (Asadpour et al. 2018). Experimental Design and Treatment Protocol Mice were randomly divided into five experimental groups and housed in separate cages as follows: normal control, uninfected, untreated control (n = 20); chamomile control (CHM), uninfected, treated with chamomile extract (100 mg/kg/day) (n = 20); Cryptosporidium (CRP), infected, untreated control (n = 20); Cryptosporidium + paromomycin (CRP+PM), infected, treated with paromomycin (100 mg/kg/day) (n = 25) and Cryptosporidium + chamomile (CRP+CHM), infected, treated with chamomile extract (100 mg/kg/day) (n = 25). The sample size for each group was determined based on previously published studies employing similar experimental models of cryptosporidiosis and comparable outcome measures. Treatment with chamomile extract or paromomycin commenced on the first day of oocyst shedding and continued for 11 consecutive days. On Days 0 (seven days post‐infection and before treatment), 3, 7 and 11 after the initiation of treatment, mice were euthanized by intravenous injection of pentobarbital (50 mg/kg) for sample collection. The remaining 5 mice in the CRP+PM and CRP+CHM. Groups were monitored for an additional 10 days to assess potential relapse (Figure 1A). Parasitological and histopathological evaluations were performed by investigators blinded to group allocation to minimize observer bias. Experimental design and effects of chamomile treatment in Cryptosporidium‐infected mice. (A) Schematic representation of the experimental design, showing animal grouping, infection with Cryptosporidium oocysts, treatment regimens and sampling time points. Mice were immunosuppressed and orally inoculated with Cryptosporidium oocysts, followed by treatment with chamomile extract (100 mg/kg/day) or paromomycin (100 mg/kg/day) for 11 consecutive days. (B) Changes in body weight (g) of mice in different experimental groups during the study period. Data are presented as mean ± SD. (C) Kaplan–Meier survival curves of mice following initiation of treatment in the different experimental groups. (D) Representative photomicrographs of Cryptosporidium oocysts detected in fecal smears stained by the modified Ziehl–Neelsen method, illustrating oocyst shedding during infection. It should be noted that, mice euthanized at predefined time points (Days 0, 3, 7 and 11) for sample collection were treated as censored observations in the survival analysis. Kaplan–Meier survival curves were generated, and differences between groups were evaluated using the log‐rank (Mantel–Cox) test. Assessment of Oocyst Shedding Approximately, 20 mg of faecal samples were collected daily from each mouse in the CRP, infected, CRP+PM and CRP+CHM groups. Samples were smeared, stained using the modified Kinyoun's acid‐fast method, and examined microscopically at ×1000 magnification. The number of oocysts per 20 mg faecal sample was recorded, and results were expressed as mean ± standard error (Ortolani 2000). Histopathological Examination Following euthanasia, stomach and duodenal tissues were excised, and the remaining small intestine was fixed in 10% neutral buffered formalin. Tissue samples were processed through dehydration, clearing and paraffin embedding. Sections (5 µm) were prepared using a microtome and stained with haematoxylin–eosin (H&E). Histopathological evaluation was performed by a pathologist blinded to the treatment groups. Microscopic examination focused on villous atrophy and blunting, epithelial hyperplasia and inflammatory cell infiltration. Histopathological alterations were graded as follows: 0 = normal tissue; 1 = mild lesions; 2 = moderate lesions; 3 = severe lesions (Asadpour et al. 2018). Biochemical Assays Approximately 50 mg of intestinal tissue was collected from each mouse on Days 0, 3, 7, and 11 after treatment. Samples were rinsed with distilled water to remove debris, homogenized in PBS (PBS, 250 µL per sample), and centrifuged at 4000–6000 rpm for 20 min. The resulting supernatants were stored at −70°C until biochemical analysis. The TAC, MDA and GPx activities were quantified using commercial colorimetric assay kits (Novin Navand Salamat PishTaz, Iran) according to the manufacturer's protocols. TAC levels were measured using the ferric reducing ability of plasma (FRAP) method with Naxifer reagents, and absorbance was recorded at 593 nm after a 5‐min incubation at room temperature. Lipid peroxidation was assessed by determining MDA concentration using the thiobarbituric acid reactive substances (TBARS) assay (Nalondi kit) with absorbance read at 550 nm following a 45‐min incubation at 95°C. GPx activity was determined using Nagpix assay kits by measuring NADPH oxidation at 340 nm. Results were expressed as mmol/L Trolox equivalents for TAC, nmol/mL for MDA and nmol/min/mL for GPx, respectively. Optical densities were read using an ELx800 microplate reader (BioTek Instruments, USA). Statistical Analysis Descriptive statistics were expressed as mean ± standard deviation of the mean (SD). The normality of data distribution was assessed using the Shapiro–Wilk test. For normally distributed data, comparisons among experimental groups were performed using one‐way analysis of variance (ANOVA) followed by Tukey's post hoc test.Non‐normally distributed data, including histopathological lesion scores, were analysed using the Kruskal–Wallis test followed by Dunn's multiple comparisons test. Survival data were analysed using the Kaplan–Meier method, and differences between survival curves were evaluated using the log‐rank (Mantel–Cox) test. Heatmap visualization was used as a descriptive approach to illustrate temporal trends of measured parameters in the chamomile‐treated group. For this purpose, raw data were normalized to baseline values to improve visual interpretation. Statistical analyses were performed using SPSS software version 22.0 (SPSS Inc., Chicago, IL, USA). Graphs were generated using GraphPad Prism version 9.5 (GraphPad Software, San Diego, CA, USA). A P value of less than 0.05 was considered statistically significant. Results Body Weight Changes in body weight are shown in Figure 1B. Prior to inoculation, no significant differences in body weight were observed among the experimental groups. Following Cryptosporidium infection, mice in the infected untreated group (CRP) exhibited a progressive reduction in body weight throughout the experimental period. In contrast, treatment with chamomile extract or paromomycin mitigated infection‐associated weight loss. Mice treated with chamomile extract showed a gradual recovery of body weight during the treatment period, with values approaching those of the uninfected control groups by day 11. Similarly, paromomycin‐treated mice demonstrated partial restoration of body weight compared with the infected untreated group. No notable fluctuations in body weight were observed in the normal control or CHM groups, indicating good tolerability of chamomile administration. Survival Rate of Mice During the experimental period, mortality was recorded in each group: three deaths in the untreated Cryptosporidium‐infected group, two in the chamomile‐treated group, one in the paromomycin‐treated group and one in the uninfected control group, resulting in an overall survival rate of 93.6%. Kaplan–Meier survival analysis demonstrated significantly reduced survival in untreated infected mice compared with controls, whereas treatment with chamomile extract or paromomycin markedly improved survival, with the chamomile‐treated group showing an early stabilization in survival probability (Figure 1C). Oocyst Shedding Intensity Oocyst excretion was first detected on Day 7 post‐infection in all infected groups (CRP, CRP + PM and CRP + CHM), confirming successful infection establishment. In contrast, no oocysts were observed in the uninfected controls. Most of the infected animals exhibited mild diarrhoea or dehydration (Figure 1D). Peak oocyst excretion was observed on Day 3 after the initiation of treatment, with mean counts of 382 (359–410) oocysts in the Cryptosporidium control group, 250 (230–274) in the paromomycin‐treated group and 268 (250–283) in the chamomile‐treated group. From Day 4 onward, oocyst shedding declined progressively in both treatment groups, reaching the lowest levels by Day 11 post‐treatment. The reduction in oocyst shedding on the first day post‐treatment was not statistically significant compared with the Cryptosporidium control (p > 0.05); however, a significant decrease was recorded in the paromomycin‐treated group on Day 2 (p = 0.014). From Day 3 onward, both treated groups showed significantly lower oocyst counts compared with the untreated Cryptosporidium control group (p < 0.05). On Days 7 and 8, the chamomile‐treated group displayed a significantly greater reduction in oocyst output than the paromomycin‐treated group (p < 0.05). In contrast, at all other time points, mice treated with paromomycin had fewer oocysts than those treated with chamomile extract (p < 0.05). Complete cessation of oocyst shedding occurred on Day 12 in the paromomycin‐treated group and on Day 14 in the chamomile‐treated group, with no recurrence observed thereafter up to Day 21 (Figure 2). Variations in the number of oocysts shedding following the experimental infection and treatments in CRP, CRP + PM and CRP + CHM groups. Data are represented as Mean ± SD. The mean percentage reduction in oocyst shedding is summarized in Table 1. Paromomycin treatment achieved a 93.9% reduction by Day 11, while chamomile extract produced a comparable 91.6% reduction relative to the peak excretion observed on day 3. TABLE 1Mean percentage reduction in oocyst shedding in CRP, CRP + PM and CRP + CHM groups during the experimental period.GroupsDay 4 (%)Day 5 (%)Day 6 (%)Day 7 (%)Day 8 (%)Day 9 (%)Day 10 (%)Day 11 (%) CRP 4.7626.0948.4934.1733.7824.9624.4419.02 CRP + PM 34.5242.2848.3254.5653.2073.4489.2093.88 CRP + CHM 8.1231.6345.2365.6867.0668.7077.7579.80 Mean percentage reduction in oocyst shedding in CRP, CRP + PM and CRP + CHM groups during the experimental period. Histopathological Findings Histopathological examination of the jejunum and ileum from the normal and CHM groups revealed no detectable microscopic alterations. The intestinal architecture, including the villi, submucosa, muscularis and serosa, appeared normal, with intact epithelial lining and well‐preserved villous structures. In contrast, intestinal sections from Cryptosporidium‐infected mice exhibited marked pathological alterations compared with the uninfected controls. The observed lesions included villous blunting and broadening, epithelial atrophy and desquamation, crypt hyperplasia, inflammatory cell infiltration within the lamina propria, submucosal oedema and the presence of oocysts adherent to the epithelial surface (Figure 3). Histopathological sections of the small intestine from Cryptosporidium‐infected mice on Day 7 post‐inoculation (hematoxylin and eosin staining). (A) marked enterocytic hyperplasia; (B) Intense inflammatory cell infiltration within the lamina propria and villous broadening; (C) Villous shortening and atrophy; (D) Cryptosporidium oocysts adhering to the apical surface of intestinal villi. During post‐treatment evaluations, the severity of these lesions ranged from moderate to severe in the Cryptosporidium control group and from mild to moderate in the treated groups, with the ileum displaying more extensive damage than the jejunum. Villous shortening and cellular hyperplasia were the most frequent histopathological features in infected animals. On Day 3 post‐treatment, intestinal sections in the Cryptosporidium control group showed severe villous broadening and shortening, extensive enterocytic hyperplasia and dense infiltration of inflammatory cells in the lamina propria (Figure 4A,D). In contrast, paromomycin‐treated mice exhibited moderate improvement in mucosal structure, characterized by reduced villous thickening and moderate inflammatory cell infiltration (Figure 4B,E). Mice treated with chamomile extract showed moderate epithelial hyperplasia and less severe inflammatory infiltration than the untreated infected group (Figure 4C,F). These findings indicate an early therapeutic response in both treatment groups, particularly evident in reduced villous degeneration and inflammatory intensity. Histopathological sections of the small intestine from Cryptosporidium‐infected mice on Day 3 post‐treatment (hematoxylin and eosin staining). (A) Cryptosporidium control group demonstrating intense inflammatory cell infiltration within the lamina propria; (B) Paromomycin‐treated group exhibiting moderate inflammatory cell infiltration within the lamina propria; (C) Chamomile‐treated group showing moderate inflammatory cell infiltration in the lamina propria (D) Cryptosporidium control group showing severe villous broadening and enterocytic hyperplasia; (E) Paromomycin‐treated group showing moderate to severe villous broadening enterocytic hyperplasia; (F) Chamomile‐treated group displaying moderate enterocytic hyperplasia. By Day 7 post‐treatment, histopathological lesions in the untreated Cryptosporidium control group remained prominent, with marked epithelial desquamation, submucosal oedema, and clusters of schizonts within intestinal villi (Figure 5A–D). In treated mice, progressive mucosal recovery was observed. The paromomycin‐treated group demonstrated moderate villous regeneration with decreased inflammatory infiltration, while the chamomile‐treated group displayed milder epithelial hyperplasia and better preservation of villous shape (Figure 5E,F). The degree of inflammation and tissue disruption was significantly lower in both treated groups than in the Cryptosporidium control. Histopathological sections of the small intestine from Cryptosporidium‐infected mice on Day 7 post‐treatment (hematoxylin and eosin staining). (A) Cryptosporidium control group exhibiting marked enterocytic hyperplasia (B) Cryptosporidium control group showed marked villous shortening and atrophy; (C) Cryptosporidium control group displayed moderate inflammatory cell infiltration in the lamina propria; (D) Cryptosporidium control group showing schizonts of the parasite attached to the intestinal villi; (E) Paromomycin‐treated group showing mild to moderate enterocytic hyperplasia and slight inflammatory cell infiltration within the lamina propria; (F) Chamomile‐treated group showing mild enterocytic hyperplasia and mild inflammation. On Day 11 post‐treatment, intestinal architecture had markedly improved in both treatment groups. In the paromomycin‐treated mice, villous and crypt structures appeared nearly normal with minimal inflammatory cell infiltration. The chamomile‐treated group exhibited comparable structural restoration, with normal villous height and minimal hyperplastic changes. Conversely, the Cryptosporidium control group still showed moderate inflammatory infiltration and residual epithelial hyperplasia (Figure 6). Overall, by Day 11, both treatments effectively restored intestinal integrity, although complete normalization was slightly more evident in the chamomile‐treated mice, suggesting enhanced mucosal recovery. Histopathological sections of the small intestine from Cryptosporidium‐infected mice on Day 11 post‐treatment (hematoxylin and eosin staining). (A) Cryptosporidium control group showing moderate enterocytic hyperplasia and moderate inflammatory cell infiltration within the lamina propria; (B) Paromomycin‐treated group displaying almost normal intestinal structure with restored villous pattern and intact epithelial lining; (C) Chamomile‐treated group demonstrating nearly normal intestinal architecture with well‐preserved villi and minimal inflammatory changes. A summary of lesion severity grading is provided in Figure 6. The mean histopathological scores confirmed significant improvement (p < 0.05) in both treated groups compared with the Cryptosporidium control, with chamomile was a more effective in reducing villous distortion and inflammatory cell infiltration whereas chamomile extract displaying a more pronounced effect in attenuating enterocytic hyperplasia and epithelial desquamation (Figure 7). Semi‐quantitative histopathological scoring of intestinal lesions and therapeutic effects of paromomycin and chamomile in Cryptosporidium‐infected mice. CHM: chamomile control; CN: control normal; CRP: untreated control; CRP+PM: cryptosporidium infected treated with paromomycin (100 mg/kg/day), CRP+CHM: cryptosporidium infected treated with chamomile extract (100 mg/kg/day). Data are expressed as mean ± SD (n = 20 per group). Statistical analysis was performed using Kruskal–Wallis test followed by Dunn's multiple comparisons test. p < 0.05 is significant (# means p < 0.0001, π means p < 0.001, € means p < 0.01 and ∞ means p < 0.05 versus normal control chamomile and control groups). Oxidative Stress Biomarkers GPx Activity Changes in GPx activity across groups and time points are depicted in Figure 8A. On Day 0 (before treatment), infection with C. parvum resulted in a marked decrease in GPx levels in all infected groups (CRP, CRP + PM, CRP + CHM) compared with the normal and CHMs (p < 0.05). Following treatment, a progressive restoration of enzyme activity was observed. By Days 3 and 7 post‐treatment, GPx activity was significantly higher in both treatment groups than in the Cryptosporidium control (p < 0.01). Although GPx values in the treated groups remained slightly lower than those of the normal and CHMs at Day 7, the difference was not statistically significant (p > 0.05). By Day 11, the CHM group exhibited the highest GPx activity, whereas the Cryptosporidium control group showed the lowest (p < 0.0001). Both treated groups maintained significantly higher GPx levels compared with the untreated infected group (p < 0.01 for CRP + PM group and p = 0.002 for CRP + CHM group), although enzyme activity did not fully return to baseline. Effect of chamomile and paromomycin on intestinal oxidant/antioxidant balance parameters including GPx, TAC and MDA in Cryptosporidium‐infected mice. CHM: chamomile control; CN: control normal; CRP: untreated control; CRP+PM: cryptosporidium infected treated with paromomycin (100 mg/kg/day), CRP+CHM: cryptosporidium infected treated with chamomile extract (100 mg/kg/day). Data are expressed as mean ± SD (n = 20 per group). Statistical analysis was performed using one‐way ANOVA followed by Tukey's post hoc test. Total Antioxidant Capacity As shown in Figure 8B, C. parvum infection significantly suppressed TAC in all infected groups at Day 0 (p < 0.001). Following treatment, TAC values increased progressively in both treated groups. By Day 3, TAC in paromomycin‐ and chamomile‐treated mice was significantly higher than in the Cryptosporidium control (p = 0.028 for CRP + PM group and p = 0.045 for CRP + CHM group), and by Day 7, this increase became highly significant (p < 0.0001). Although TAC levels in treated mice remained lower than in the normal and CHMs, the gap narrowed considerably over time. By Day 11 post‐treatment, TAC had significantly improved in both treated groups relative to the Cryptosporidium control (p = 0.002 for CRP + PM group and p = 0.02 for CRP + CHM group), indicating partial restoration of systemic antioxidant capacity. MDA Concentration Figure 8C presents the variations in MDA levels. C. parvum infection induced a significant rise in MDA concentration at Day 0 in all infected groups compared with normal controls (p < 0.001), indicating enhanced lipid peroxidation. On Day 3 post‐treatment, MDA levels peaked in the Cryptosporidium control, while treated groups showed a significant reduction (p < 0.0001 for CRP + PM group and p = 0.003 for CRP + CHM group). However, MDA levels in these groups remained higher than in the uninfected controls (p < 0.001). By Day 7, a pronounced decline in MDA was detected in both treatment groups compared with the Cryptosporidium control (p < 0.001). On Day 11 post‐treatment, the Cryptosporidium control group maintained the highest MDA level among all groups (p < 0.01), while MDA concentrations in the treated groups approached normal control levels, and differences between the treated and control groups were no longer statistically significant (p > 0.05). These findings collectively indicate that both paromomycin and chamomile extract effectively mitigated oxidative stress and lipid peroxidation induced by C. parvum infection. Discussion Cryptosporidium species are obligate intracellular protozoan parasites that infect a broad range of vertebrate hosts, including humans and domestic animals, leading to significant health and economic impacts worldwide. The severity and outcome of cryptosporidiosis largely depend on the host immune status, particularly the integrity of cell‐mediated immunity (Ryan et al. 2016; Ward 2017). Despite several decades of research, no fully effective anti‐cryptosporidial drug or vaccine has been developed. Nitazoxanide, the only FDA‐approved drug, demonstrates variable efficacy, especially in immunocompromised patients, whereas paromomycin yields inconsistent outcomes and frequent relapse (Asadpour et al. 2018; Ryan et al. 2016). Consequently, the search for novel therapeutic agents remains a priority in both human and veterinary parasitology. The growing body of evidence supports the therapeutic potential of herbal compounds in the management of protozoan infections, including cryptosporidiosis. Recent comprehensive analyses (Namazi and Razavi 2024) have emphasized that phytochemicals such as flavonoids, phenolic acids, terpenoids and coumarins can target multiple pathways in Cryptosporidium infection, including oxidative stress regulation, mitochondrial‐mediated apoptosis and suppression of proinflammatory cytokines. These previously proposed mechanisms may provide a plausible explanation for the beneficial effects observed in the present study; however, they were not directly investigated. Our findings revealed that chamomile treatment markedly reduced oocyst shedding, improved intestinal histoarchitecture and enhanced antioxidant defence by increasing TAC and GPx activity while reducing MDA levels in immunosuppressed mice experimentally infected with C. parvum. These findings collectively suggest that the protective effects of chamomile may be associated with improvements in oxidative status, intestinal histopathology and reduced oocyst shedding. While no previous study has directly investigated chamomile's activity against C. parvum, its antiparasitic efficacy has been reported against other protozoa and helminths. Methanolic extracts of M. chamomilla exhibit strong anti‐Acanthamoeba castellanii effects, attributed to coumarin derivatives, while α‐bisabolol—one of its principal sesquiterpenes—shows potent amoebicidal activity through apoptosis induction, ATP depletion, and increased membrane permeability (Akkari 2017). Moreover, chamomile essential oils and α‐bisabolol have shown remarkable leishmanicidal effects against both promastigote and amastigote forms of Leishmania amazonensis and L. infantum, mediated by apoptotic and oxidative pathways (Andrade et al. 2016; Hajaji et al. 2018b). Its methanol extract also demonstrates significant ovicidal and larvicidal activity against Haemonchus contortus, reducing egg hatching and larval development by 37.5% and 84%, respectively (Hajaji et al. 2018a; Váradyová et al. 2018). These data collectively suggest that chamomile's bioactive constituents—particularly α‐bisabolol and coumarins—target parasite metabolism and integrity through oxidative and apoptotic mechanisms. Considering that C. parvum suppresses host cell apoptosis via survivin (BIRC5) overexpression (Liu et al. 2008), the pro‐apoptotic activity of chamomile could counteract this mechanism, limiting parasite replication. The significant decrease in oocyst shedding and amelioration of mucosal lesions in our study could therefore be attributed, at least in part, to such mechanisms. Cryptosporidium‐induced oxidative stress results from excessive production of ROS, leading to lipid peroxidation, reduced antioxidant defences, and cellular apoptosis (Elmahallawy et al. 2020). In our study, C. parvum infection led to marked increases in MDA levels and significant reductions in TAC and GPx activity, indicating severe oxidative imbalance. Chamomile treatment effectively reversed these alterations, reflecting its strong antioxidant potential. The antioxidant activity of M. chamomilla has been widely demonstrated in vitro and in vivo. Methanolic extracts possess the highest radical‐scavenging potential in the 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) radical scavenging assay, the 2,2′‐azino‐bis (3‐ethylbenzothiazoline‐6‐sulfonic acid (ABTS) assay, the oxygen radical absorbance capacity (ORAC) test and the ferric reducing antioxidant power (FRAP) assay, outperforming other extraction types and essential oils (Moharram and Youssef 2014). Polyphenolic compounds such as luteolin and luteolin‐7‐O‐β‐D‐glucuronide, and terpenoids such as chamazulene, have demonstrated potent antioxidant properties, in some cases exceeding those of standard antioxidants such as α‐tocopherol and butylated hydroxytoluene (BHT). These molecules can neutralize ROS directly and upregulate endogenous antioxidant enzymes, which aligns with our observed increases in GPx and TAC following chamomile administration (Franco et al. 2018). By restoring redox balance, chamomile likely protected intestinal epithelial cells from oxidative damage, reducing villous atrophy and promoting mucosal repair. This is consistent with earlier studies reporting the tissue‐protective effects of chamomile in gastric and oral ulcer models (Oliveira et al. 2016; El Souda et al. 2015). In the present study, histological analysis revealed severe villous blunting and broadening, epithelial desquamation, crypt hyperplasia, submucosal oedema and inflammatory cell infiltration in infected untreated mice—findings consistent with the enteropathogenic mechanism of C. parvum (Asadpour et al. 2018; Ganai et al. 2021). In contrast, both paromomycin and chamomile treatments attenuated these lesions, with evident reductions in inflammatory cell infiltration and enterocyte hyperplasia by Day 11 post‐treatment. The attenuation of inflammation may be linked to the inhibitory effects of chamomile's flavonoids and sesquiterpenes on proinflammatory mediators. Apigenin‐7‐glucoside, the dominant flavonoid in chamomile, suppresses TNF‐α production in macrophages, and matricine reduces TNF‐α and ICAM‐1 expression through NF‐κB inhibition in endothelial cells (Sánchez et al. 2022). These previously reported activities may partly contribute to the reduced inflammatory infiltration and improved tissue integrity observed in the present study. In agreement with previous findings, paromomycin markedly reduced both oocyst shedding and intestinal tissue injury, confirming its partial yet consistent efficacy against C. parvum (Asadpour et al. 2018; Whitta et al. 2024). Nevertheless, mice treated with M. chamomilla extract exhibited a more gradual but sustained improvement throughout the experimental period, suggesting that chamomile may exert its therapeutic effects through a multifactorial mechanism rather than solely through direct parasitic inhibition. The progressive reduction in oocyst output, together with restoration of mucosal architecture and enhancement of antioxidant defences, suggests that chamomile may exert both parasite‐directed and host‐supportive effects. However, the precise molecular and immunological mechanisms underlying these effects remain to be determined. These observations are consistent with reports on other phytotherapeutic agents exhibiting combined antioxidant, anti‐inflammatory and immunomodulatory activities. Extracts of Artemisia spicigera, Curcuma longa, Allium sativum and Punica granatum have all demonstrated significant anti‐cryptosporidial efficacy by reducing oocyst burden and promoting intestinal recovery (Namazi and Razavi 2024). Similarly, plant‐derived polyphenols and flavonoids such as curcumin and mangiferin have been shown to suppress parasite replication, mitigate oxidative tissue damage and enhance host immune responses. Collectively, these findings support the growing concept that natural antioxidants—including chamomile—may serve as potential adjuncts or alternative therapies in the management of cryptosporidiosis, particularly in immunocompromised hosts where conventional drugs. Although this study was conducted in an experimental murine model, the findings may have translational relevance to immunocompromised human patients, such as HIV/AIDS individuals, where cryptosporidiosis remains a significant cause of morbidity. Limitations Although the present study demonstrated beneficial therapeutic effects of M. chamomilla in an experimental model of cryptosporidiosis, several limitations should be acknowledged. First, the commercial M. chamomilla preparation used in this study was not independently characterized or standardized, and its phytochemical composition was based on the manufacturer's specifications. Nevertheless, the reported phytochemical profile was consistent with previously published analyses of hydroalcoholic M. chamomilla extracts. Second, although comprehensive parasitological, biochemical, oxidative stress and histopathological evaluations were performed, direct immunological and molecular analyses, such as cytokine profiling, immune cell characterization and assessment of apoptosis‐related signalling pathways, were beyond the scope of the present study. Therefore, the therapeutic effects observed were interpreted primarily on the basis of parasitological, histopathological and oxidative stress findings, while the underlying molecular and immunological mechanisms remain to be elucidated. Finally, the study employed a single‐dose, relatively short‐term treatment protocol. Consequently, dose–response relationships, the optimal therapeutic dose and the long‐term efficacy of M. chamomilla could not be assessed. Future studies incorporating standardized phytochemical characterization, comprehensive immunological and molecular investigations, multiple dosage regimens and extended treatment and follow‐up periods are warranted to further characterize the therapeutic potential and mechanisms of action of M. chamomilla in cryptosporidiosis. Conclusion In conclusion, the hydroalcoholic extract of M. chamomilla was associated with reduced oocyst shedding, improved intestinal histopathological architecture and enhanced antioxidant status in immunosuppressed mice infected with C. parvum (Figure 9). The observed therapeutic effects may be related to a combination of parasite‐related and host‐supportive actions; however, the underlying molecular and immunological mechanisms were not investigated in the present study. These findings support the potential of M. chamomilla as a promising adjunctive phytotherapeutic approach for cryptosporidiosis and justify further mechanistic, pharmacological and long‐term studies. Temporal heatmap of chamomile's therapeutic effects on cryptosporidium infection parameters. Z‐score normalized mean values (n = 20/time point) across Days 0–11, with Day 0 as pre‐treatment baseline. Blue shades denote values below overall mean (favorable for MDA, oocyst count, lesion score); red shades denote values above mean (favorable for GPx, TAC). Numerical annotations represent % change from Day 0 baseline. GPx: glutathione peroxidase; MDA: malondialdehyde; TAC: total antioxidant capacity. Author Contributions Kousha Kiani: investigation, data curation, resources. Mohammad Hashemnia: conceptualization, formal analysis, investigation, methodology, data curation, validation, project administration, visualization, supervision, writing – review and editing. Farid Rezaei: formal analysis, methodology. Hadi Cheraghi: validation, formal analysis, methodology. All authors have read and approved the manuscript. Funding The authors have nothing to report. Ethics Statement This study was performed under the approval of the State Committee on Animal Ethics, Razi University, Kermanshah, Iran (IR.RAZI.AEC.1401.045). In addition, recommendations of the European Council Directive (86/609/EC) of 24 November 1986, regarding the protection of animals used for experimental purposes were considered. This article does not contain any studies with human participants performed by any of the authors. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements The authors wish to express their sincere appreciation to Mrs. Sara Fallahi, Laboratory Technician at the Department of Pathology, Faculty of Veterinary Medicine, Razi University, for her valuable technical assistance and support during the histopathological examinations. Data Availability Statement The datasets generated the current study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The datasets generated the current study are available from the corresponding author upon reasonable request.